Journal: Biochemical Journal

Article Title: The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase

doi: 10.1042/BCJ20230035

Figure Lengend Snippet:

Article Snippet: Human RIPK3 , Rat anti-human RIPK3 clone 1H2 , Produced in-house [ ], available from Merck Millipore , cat #MABC1640 , 1 : 1000.

Techniques: Western Blot, Produced, Phospho-proteomics, Transduction

Journal: Discover Oncology

Article Title: Comprehensive investigation identifies CPSF3 as a novel prognostic and oncogenic biomarker in bladder cancer

doi: 10.1007/s12672-025-03672-z

Figure Lengend Snippet: CPSF3 expression in different human tissues. A Expression pattern of CPSF3 in 33 types of tumor tissues and para-tumor tissues. B Differences in CPSF3 expression between BC tissues and normal bladder tissues. C Pairwise difference analysis of CPSF3 in BC tissues and paired para-tumor tissues. D Differences in CPSF3 expression between BC samples and para-tumor samples. E Representative microphotographs of CPSF3 expression in tumor and para-tumor tissues. (F) CPSF3 mRNA expression in BC and normal cells. G CPSF3 protein expression in BC and normal cells. Data of A - C were collected from the TCGA databases. Data of D - E were collected from Ruijin cohort. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: Following that, TMAs were washed using PBS buffer 3 times and added with primary antibody against human CPSF3 (1:50 dilution, rabbit, Abmart) overnight at 4°C temperature.

Techniques: Expressing

Journal: Discover Oncology

Article Title: Comprehensive investigation identifies CPSF3 as a novel prognostic and oncogenic biomarker in bladder cancer

doi: 10.1007/s12672-025-03672-z

Figure Lengend Snippet: Gene mutation, DNA methylation profiles and distribution in multiple cell types of CPSF3. A CNV alteration frequency of CSPF3 in TCGA cancers via cBioPortal database. B Correlation between CPSF3 expression and copy-number values. C Correlation between CPSF3 expression and promoter methylation. D Waterfall plot showing the somatic mutation landscape of CPSF3 in BLCA with top 10 mutation genes displayed. E Comparison of gene mutations between CPSF3-high and CPSF3-low groups in BLCA. F Major immune cell populations in the TME of BC. G The distribution of CPSF3 expression in various immune cell populations. H Violin plot displaying CPSF3 expression in various immune cell populations. I Correlation between CPSF3 expression and 24 tumor-infiltrating immune cell types. J Correlation between CPSF3 expression and common immune checkpoints (ICPs). Data were obtained from the GEO ( GSE149652 ) and TCGA databases. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Following that, TMAs were washed using PBS buffer 3 times and added with primary antibody against human CPSF3 (1:50 dilution, rabbit, Abmart) overnight at 4°C temperature.

Techniques: Mutagenesis, DNA Methylation Assay, Expressing, Methylation, Comparison

Journal: Discover Oncology

Article Title: Comprehensive investigation identifies CPSF3 as a novel prognostic and oncogenic biomarker in bladder cancer

doi: 10.1007/s12672-025-03672-z

Figure Lengend Snippet: Role of CPSF3 in predicting prognosis of patients from Ruijin cohort and validation. A - B Correlation analysis between the different expression levels of CPSF3 and OS, DFS in TCGA-BLCA datasets. C - D Correlation analysis between the different expression levels of CPSF3 and OS, DFS in Ruijin cohort. E Nomogram for predicting 1-year, 3-year and 5-year OS. F Nomogram for predicting 1-year, 3-year and 5-year DFS. G , H Calibration curves of 1-year, 3-year and 5-year for OS in the training cohor and the internal validation cohort. I - J Calibration curves of 1-year, 3-year and 5-year for DFS in the training cohort and the validation cohort. (K)-(L) ROC curves of 1-year, 3-year and 5-year OS in the training cohort and the internal validation cohort. M - N ROC curves of 1-year, 3-year and 5-year DFS in the training cohort and the internal validation cohort. Data were collected from the TCGA databases and Ruijin cohort

Article Snippet: Following that, TMAs were washed using PBS buffer 3 times and added with primary antibody against human CPSF3 (1:50 dilution, rabbit, Abmart) overnight at 4°C temperature.

Techniques: Biomarker Discovery, Expressing

Journal: Discover Oncology

Article Title: Comprehensive investigation identifies CPSF3 as a novel prognostic and oncogenic biomarker in bladder cancer

doi: 10.1007/s12672-025-03672-z

Figure Lengend Snippet: Influence of siRNA on CPSF3 expression and BC cell growth. A - C Transfection effect of siRNA in T24 and UMUC3 on mRNA and protein level. (D)-(E) CCK-8 assay showing the influence of CPSF3 downregulation on the cell proliferation. F - G The colony formation assay showing the influence of CPSF3 downregulation on the cell clonogenic capacity. H The subcutaneous xenograft tumor models 28 days after UMUC3 cells injection. I The dissected subcutaneous tumors in two groups. J Body weights and tumor volumes in two groups. * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001

Article Snippet: Following that, TMAs were washed using PBS buffer 3 times and added with primary antibody against human CPSF3 (1:50 dilution, rabbit, Abmart) overnight at 4°C temperature.

Techniques: Expressing, Transfection, CCK-8 Assay, Colony Assay, Injection

Journal: Discover Oncology

Article Title: Comprehensive investigation identifies CPSF3 as a novel prognostic and oncogenic biomarker in bladder cancer

doi: 10.1007/s12672-025-03672-z

Figure Lengend Snippet: Influence CPSF3 expression on BC cell cycle. A Top ten KEGG enrichment pathways. B GSEA of cell cycle pathway. C GSEA of cell cycle checkpoints pathway. D - E The cell cycle distribution of T24 and UMUC3 detected by flow cytometry and histograms showng the percentages of each cell cycle phase. F CDK4, CDK6 and Cyclin D1 protein expression with altered CPSF3 expression in T24 and UMUC3. * P < 0.05, ** P < 0.01

Article Snippet: Following that, TMAs were washed using PBS buffer 3 times and added with primary antibody against human CPSF3 (1:50 dilution, rabbit, Abmart) overnight at 4°C temperature.

Techniques: Expressing, Flow Cytometry